Have any questions? 706-721-6582 or cts@augusta.edu
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimer’s Disease
Clinical Trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimer’s Disease
The purpose of this study is to assess the effectiveness the study drug, KarXT, to determine whether or not the study drug reduces symptoms in the treatment of psychosis associated with AD.
Eligibility Criteria
- Patients must be between 55 to 90 years old Capable of walking and have an identified study partner who should have daily contact History of psychotic symptoms
RESEARCH. INNOVATION. DISCOVERY.